AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10750670 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 100)
Number of subjects: 201
Study 10750670 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 101)
Number of subjects: 201
Study 9623429 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 84
Study 9623429 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 84
Study 9623429 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 84
Study 9623429 — intervention group
Group type: COMPARATOR
Intervention: TIVA
Number of subjects: 84
Study 7837074 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 mm sutureless incisions
Number of subjects: 80
Study 7837074 — intervention group
Group type: COMPARATOR
Intervention: 5.1 mm sutureless incisions
Number of subjects: 80
Study 2980629 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission to a nursing unit where nursing was perceived as the chief therapeutic activity
Number of subjects: 0
Study 2980629 — intervention group
Group type: COMPARATOR
Intervention: Normal patient pathway (control group)
Number of subjects: 0
Study 29468446 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term temozolomide therapy
Number of subjects: 0
Study 29468446 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (short-term temozolomide)
Number of subjects: 0
Study 28174170 — intervention group
Group type: EXPERIMENTAL
Intervention: AF‐Defrag group (n=29)
Number of subjects: 137
Study 28174170 — intervention group
Group type: COMPARATOR
Intervention: CPVI+Line group (n=54)
Number of subjects: 137
Study 28174170 — intervention group
Group type: EXPERIMENTAL
Intervention: CPVI+Line+CFAE group (n=54)
Number of subjects: 137
Study 28174170 — intervention group
Group type: EXPERIMENTAL
Intervention: CPVI+Line+CFAE group
Number of subjects: 137
Study 28174170 — intervention group
Group type: COMPARATOR
Intervention: CPVI+Line group
Number of subjects: 137
Study 28174170 — intervention group
Group type: COMPARATOR
Intervention: CPVI+Line+CFAE group and CPVI+Line group
Number of subjects: 137
Study 26168672 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjoined tendon reconstruction group (n = 36)
Number of subjects: 74
Study 26168672 — intervention group
Group type: EXPERIMENTAL
Intervention: Tractusiliotibialis reconstruction group (n = 38)
Number of subjects: 74
Study 23943217 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical decompression
Number of subjects: 39
Study 23943217 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment
Number of subjects: 39
Study 21388444 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 268
Study 21388444 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 268
Study 21388444 — intervention group
Group type: EXPERIMENTAL
Intervention: Parasympathetic dysfunction
Number of subjects: 268
Study 21388444 — intervention group
Group type: EXPERIMENTAL
Intervention: E/I ratio correlations
Number of subjects: 268
Study 18347350 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk adenomas (defined as > or =3 adenomas or any advanced adenomas)
Number of subjects: 1905
Study 18347350 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk adenomas (defined as 2 or fewer nonadvanced adenomas)
Number of subjects: 1905
Study 18347350 — intervention group
Group type: COMPARATOR
Intervention: High-risk adenomas
Number of subjects: 1905
Study 16969592 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg administered intravenously every 3 months
Number of subjects: 23
Study 12954157 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 8 mg/day
Number of subjects: 10
Study 12212156 — intervention group
Group type: EXPERIMENTAL
Intervention: PN with lower energy (105 KJ.kg‐1.d‐1)
Number of subjects: 30
Study 12212156 — intervention group
Group type: COMPARATOR
Intervention: PN with higher energy (146 KJ.kg‐1.d‐1)
Number of subjects: 30
Study 8818849 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg azithromycin, administered orally once daily for 3 days
Number of subjects: 440
Study 8818849 — intervention group
Group type: COMPARATOR
Intervention: 150 mg roxithromycin, given orally twice daily for 10 days
Number of subjects: 440
Study 8818849 — intervention group
Group type: EXPERIMENTAL
Intervention: azithromycin
Number of subjects: 440
Study 8818849 — intervention group
Group type: COMPARATOR
Intervention: roxithromycin
Number of subjects: 440
Study 7819707 — intervention group
Group type: EXPERIMENTAL
Intervention: buserelin-long
Number of subjects: 0
Study 7819707 — intervention group
Group type: COMPARATOR
Intervention: buserelin-short
Number of subjects: 0
Study 7819707 — intervention group
Group type: EXPERIMENTAL
Intervention: leuprolide-long
Number of subjects: 0
Study 7819707 — intervention group
Group type: COMPARATOR
Intervention: leuprolide-short
Number of subjects: 0
Study 3052116 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse home visitation
Number of subjects: 0
Study 3052116 — intervention group
Group type: COMPARATOR
Intervention: Comparison services
Number of subjects: 0
Study 30118904 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid light activation (HL) with prior enamel acid etching (37% phosphoric acid for 15s) and 35% hydrogen peroxide gel (HP) applied for 3-4 consecutive applications with 2×3' activations (1' interval)
Number of subjects: 34
Study 30118904 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid light activation (HL) without prior enamel acid etching and 35% hydrogen peroxide gel (HP) applied for 3-4 consecutive applications with 2×3' activations (1' interval)
Number of subjects: 34
Study 30118904 — intervention group
Group type: COMPARATOR
Intervention: Control group (GIII and IV) without HL, receiving 35% hydrogen peroxide gel (HP) applied for 3×15' without HL
Number of subjects: 34
Study 25682724 — intervention group
Group type: EXPERIMENTAL
Intervention: Duct to mucosa pancreaticojejunostomy (G1)
Number of subjects: 107
Study 25682724 — intervention group
Group type: COMPARATOR
Intervention: Invagination pancreaticojejunostomy (G2)
Number of subjects: 107
Study 23726721 — intervention group
Group type: EXPERIMENTAL
Intervention: Always abstinent
Number of subjects: 0
Study 23726721 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluctuating use, abuse, and occasional abstinence
Number of subjects: 0
Study 23726721 — intervention group
Group type: EXPERIMENTAL
Intervention: Occasional (ab)use
Number of subjects: 0
Study 23726721 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopped (ab)use
Number of subjects: 0
Study 23726721 — intervention group
Group type: EXPERIMENTAL
Intervention: Abusing
Number of subjects: 0
Study 20846200 — intervention group
Group type: EXPERIMENTAL
Intervention: LEC group - levofloxacin 500 mg, esomeprazole 40 mg, clarithromycin 500 mg once daily for 7 days
Number of subjects: 189
Study 20846200 — intervention group
Group type: COMPARATOR
Intervention: AEC group - amoxicillin 1 g, esomeprazole 40 mg, clarithromycin 500 mg twice daily for 7 days
Number of subjects: 189
Study 20846200 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 189
Study 18223614 — intervention group
Group type: EXPERIMENTAL
Intervention: 26% dietary fat treatment
Number of subjects: 22
Study 18223614 — intervention group
Group type: EXPERIMENTAL
Intervention: 34% dietary fat treatment
Number of subjects: 22
Study 18223614 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% dietary fat treatment
Number of subjects: 22
Study 16565237 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (40 to 80 mg)
Number of subjects: 250
Study 16565237 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (10 to 20 mg)
Number of subjects: 250
Study 16565237 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan and Enalapril
Number of subjects: 250
Study 14578725 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg)
Number of subjects: 80
Study 14578725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 10937427 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough induced with inhaled citric acid
Number of subjects: 30
Study 10937427 — intervention group
Group type: COMPARATOR
Intervention: Control condition (estimation of lemon flavors)
Number of subjects: 30
Study 10937427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10937427 — intervention group
Group type: EXPERIMENTAL
Intervention: Thresholds for citric acid (50% of thresholds)
Number of subjects: 30
Study 9017582 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin or carboplatin containing chemotherapy
Number of subjects: 1052
Study 1460118 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin cream, applied once nightly for 36 weeks
Number of subjects: 776
Study 1460118 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream, applied once nightly for 36 weeks
Number of subjects: 776
Study 6381871 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin (0.075 IU/kg)
Number of subjects: 0
Study 6381871 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine insulin (0.075 IU/kg)
Number of subjects: 0
Study 6381871 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin (0.12 IU/kg)
Number of subjects: 0
Study 6381871 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine insulin (0.12 IU/kg)
Number of subjects: 0
Study 6381871 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin
Number of subjects: 0
Study 6381871 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin and Porcine insulin
Number of subjects: 0
Study 31113795 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5069
Number of subjects: 0
Study 31113795 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD4721
Number of subjects: 0
Study 30829265 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiotherapy (IMRT)
Number of subjects: 64
Study 26875824 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine-Rituximab (BR)
Number of subjects: 0
Study 26875824 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP/R-CVP (standard therapy)
Number of subjects: 0
Study 25382402 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (2000 IU 3×/week)
Number of subjects: 19
Study 25382402 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 19
Study 22350925 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release melatonin (PR-M) 2 mg
Number of subjects: 24
Study 22350925 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem 10 mg (active control)
Number of subjects: 24
Study 22350925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 20827170 — intervention group
Group type: EXPERIMENTAL
Intervention: Uridine (NucleomaxX)
Number of subjects: 165
Study 20827170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 17577041 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 9970
Study 17577041 — intervention group
Group type: COMPARATOR
Intervention: FU-based combination chemotherapy
Number of subjects: 9970
Study 17577041 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine
Number of subjects: 9970
Study 17577041 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine combination chemotherapy
Number of subjects: 9970
Study 16030464 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based system for continence health promotion (n = 36)
Number of subjects: 71
Study 16030464 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group using an alternate system (n = 35)
Number of subjects: 71
Study 12042621 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct stenting without predilatation (group I)
Number of subjects: 145
Study 12042621 — intervention group
Group type: COMPARATOR
Intervention: Stenting with predilatation (group II)
Number of subjects: 145
Study 10450005 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP)
Number of subjects: 26
Study 10450005 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NP)
Number of subjects: 26
Study 7781622 — intervention group
Group type: EXPERIMENTAL
Intervention: Iatrogenic hypercortisolemia treatment for underlying diseases in pregnant women
Number of subjects: 0
Study 2403833 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 219
Study 2403833 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate
Number of subjects: 219
Study 363335 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine salicylate
Number of subjects: 12
Study 31785550 — intervention group
Group type: EXPERIMENTAL
Intervention: Racially concordant/discordant video-based decision support tool
Number of subjects: 350
Study 31785550 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 350
Study 31785550 — intervention group
Group type: EXPERIMENTAL
Intervention: Racially concordant video
Number of subjects: 350
Study 31785550 — intervention group
Group type: EXPERIMENTAL
Intervention: Racially discordant video
Number of subjects: 350
Study 30694917 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg daily
Number of subjects: 631
Study 30694917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 631
Study 28658165 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy (invasive procedures such as endoscopic injection sclerotherapy or endoscopic band ligation) for esophageal varices
Number of subjects: 51
Study 28658165 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased SMI group (n=15)
Number of subjects: 51
Study 28658165 — intervention group
Group type: EXPERIMENTAL
Intervention: BTR as a prognostic factor
Number of subjects: 51
Study 26119895 — intervention group
Group type: EXPERIMENTAL
Intervention: mini-open TLIF
Number of subjects: 3
Study 26119895 — intervention group
Group type: EXPERIMENTAL
Intervention: corrective TLIF
Number of subjects: 3
Study 26119895 — intervention group
Group type: COMPARATOR
Intervention: corrective TLIF with instrumentation-related complications
Number of subjects: 3
Study 24013130 — intervention group
Group type: EXPERIMENTAL
Intervention: rtfMRI training sessions to up-regulate DLPFC activation
Number of subjects: 0
Study 24013130 — intervention group
Group type: EXPERIMENTAL
Intervention: rtfMRI training sessions
Number of subjects: 0
Study 24013130 — intervention group
Group type: COMPARATOR
Intervention: Control group (sham feedback)
Number of subjects: 0
Study 20861416 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide-based anesthesia
Number of subjects: 2050
Study 20861416 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide-free anesthesia
Number of subjects: 2050
Study 19223606 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial group rehabilitation intervention
Number of subjects: 235
Study 16687711 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (88 mcg twice daily)
Number of subjects: 285
Study 16687711 — intervention group
Group type: COMPARATOR
Intervention: Masked placebo
Number of subjects: 285
Study 14704799 — intervention group
Group type: EXPERIMENTAL
Intervention: Convergent dynamic random-dot stereograms (DRDS)
Number of subjects: 0
Study 14704799 — intervention group
Group type: EXPERIMENTAL
Intervention: Divergent dynamic random-dot stereograms (DRDS)
Number of subjects: 0
Study 14704799 — intervention group
Group type: EXPERIMENTAL
Intervention: Convergent DRDS
Number of subjects: 0
Study 14704799 — intervention group
Group type: EXPERIMENTAL
Intervention: Divergent DRDS
Number of subjects: 0
Study 11742776 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of external hip protectors and encouragement by nurses to use the protectors
Number of subjects: 174
Study 11742776 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hip protectors)
Number of subjects: 174
Study 11742776 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of external hip protectors
Number of subjects: 174
Study 9431483 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 30
Study 9431483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8219947 — intervention group
Group type: EXPERIMENTAL
Intervention: Senna-fibre combination (10 ml daily)
Number of subjects: 77
Study 8219947 — intervention group
Group type: COMPARATOR
Intervention: Lactulose (15 ml twice daily)
Number of subjects: 77
Study 8219947 — intervention group
Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 77
Study 8219947 — intervention group
Group type: EXPERIMENTAL
Intervention: Senna-fibre combination
Number of subjects: 77
Study 8219947 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 77
Study 3676920 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 0
Study 3676920 — intervention group
Group type: COMPARATOR
Intervention: L-Dopa (Sinemet)
Number of subjects: 0
Study 29282600 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin 75 mg/m2 for 60 min at 43 °C
Number of subjects: 33
Study 29282600 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 33
Study 27092908 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Millard repair with alar base incision
Number of subjects: 0
Study 27092908 — intervention group
Group type: COMPARATOR
Intervention: Intranasal wide dissection
Number of subjects: 0
Study 25047090 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (4 g/day)
Number of subjects: 205
Study 25047090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 22247489 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity
Number of subjects: 255
Study 22247489 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision-related function score (NEI VFQ-25)
Number of subjects: 255
Study 22247489 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual function score
Number of subjects: 255
Study 20520601 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg caffeine followed by 150 mg caffeine 90 min later
Number of subjects: 379
Study 20520601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 379
Study 20520601 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (100 mg and 150 mg)
Number of subjects: 379
Study 20520601 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (frequent consumption)
Number of subjects: 379
Study 18937268 — intervention group
Group type: EXPERIMENTAL
Intervention: Appearance-focused intervention (booklet based on decision-theoretical models of health behavior)
Number of subjects: 430
Study 18937268 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 430
Study 18937268 — intervention group
Group type: EXPERIMENTAL
Intervention: Appearance-focused intervention
Number of subjects: 430
Study 17003661 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 376
Study 17003661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 376
Study 12704369 — intervention group
Group type: EXPERIMENTAL
Intervention: Long synthetic overlapping peptides (LSP) immunotherapy, 100 microg per peptide, injected at days 0, 4, 7, 14, 42, and 70.
Number of subjects: 0
Study 12704369 — intervention group
Group type: COMPARATOR
Intervention: Control group injected with human albumin.
Number of subjects: 0
Study 10890620 — intervention group
Group type: EXPERIMENTAL
Intervention: NIMV with a nasal mask
Number of subjects: 26
Study 10890620 — intervention group
Group type: EXPERIMENTAL
Intervention: NIMV with a full‐face mask
Number of subjects: 26
Study 10890620 — intervention group
Group type: EXPERIMENTAL
Intervention: NIMV with nasal plugs
Number of subjects: 26
Study 10890620 — intervention group
Group type: COMPARATOR
Intervention: NIMV with assist control or pressure‐assisted modes
Number of subjects: 26
Study 8956953 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood samples collected from patients with multiple injuries
Number of subjects: 40
Study 1347267 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg
Number of subjects: 16
Study 1347267 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 20 mg
Number of subjects: 16
Study 1347267 — intervention group
Group type: COMPARATOR
Intervention: Clemastine 2 mg
Number of subjects: 16
Study 1347267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3160266 — intervention group
Group type: EXPERIMENTAL
Intervention: HealthScan Assess peak flow meter
Number of subjects: 0
Study 3160266 — intervention group
Group type: COMPARATOR
Intervention: Standard Wright Peak Flow Meter
Number of subjects: 0
Study 3160266 — intervention group
Group type: EXPERIMENTAL
Intervention: HealthScan Assess peak flow meters (six units)
Number of subjects: 0
Study 31496423 — intervention group
Group type: EXPERIMENTAL
Intervention: Community empowerment-based model of combination HIV prevention
Number of subjects: 0
Study 27171538 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted physical activity-based rehabilitation (N=304)
Number of subjects: 321
Study 27171538 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 321
Study 27023447 — intervention group
Group type: EXPERIMENTAL
Intervention: TSH ≥ 2.5 mIU/L
Number of subjects: 0
Study 27023447 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid autoimmunity
Number of subjects: 0
Study 27023447 — intervention group
Group type: COMPARATOR
Intervention: TSH < 2.5 mIU/L
Number of subjects: 0
Study 23873889 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D roadmap technique
Number of subjects: 40
Study 23873889 — intervention group
Group type: COMPARATOR
Intervention: 2D roadmap technique
Number of subjects: 40
Study 22410350 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser peripheral iridotomy (LPI)
Number of subjects: 176
Study 20463178 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 microg
Number of subjects: 1683
Study 20463178 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 microg
Number of subjects: 1683
Study 20463178 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg
Number of subjects: 1683
Study 20463178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1683
Study 18360012 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (20 mg/day)
Number of subjects: 20